Receive Our Newsletter

Sangamo Therapeutics And Pfizer Announce Collaboration For Hemophilia A Gene Therapy


Sangamo Therapeutics, Inc. and Pfizer Inc. recently announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of Sangamo’s four lead product candidates, which Sangamo expects will enter the clinic this quarter. Click here to read the full press release from Sangamo Therapeutics.

Comments (No comments)

Assisting and Advocating for the Bleeding Disorders Community